Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Rating of “Hold” by Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX) has earned an average recommendation of “Hold” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $23.50.

A number of equities research analysts have weighed in on the company. Truist Financial lowered Pacira BioSciences from a “buy” rating to a “sell” rating and lowered their price objective for the company from $30.00 to $8.00 in a report on Tuesday, August 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Pacira BioSciences in a report on Friday, November 8th. StockNews.com downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 12th. Raymond James downgraded shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research report on Monday, August 12th. Finally, Jefferies Financial Group lifted their price target on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th.

Pacira BioSciences Price Performance

Shares of PCRX opened at $19.09 on Friday. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $35.95. The stock’s 50 day moving average is $16.68 and its two-hundred day moving average is $19.56. The firm has a market capitalization of $881.44 million, a PE ratio of -9.40 and a beta of 0.80. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PCRX. GAMMA Investing LLC raised its holdings in Pacira BioSciences by 229.6% in the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after acquiring an additional 932 shares during the last quarter. Park Place Capital Corp acquired a new position in Pacira BioSciences in the 2nd quarter valued at $46,000. Innealta Capital LLC acquired a new position in Pacira BioSciences in the 2nd quarter valued at $50,000. nVerses Capital LLC raised its holdings in Pacira BioSciences by 800.0% in the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after acquiring an additional 1,600 shares during the last quarter. Finally, CWM LLC raised its holdings in Pacira BioSciences by 713.6% in the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after acquiring an additional 5,716 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.